Avenue Therapeutics (ATXI) Expected to Announce Quarterly Earnings on Monday

by · The Cerbat Gem

Avenue Therapeutics (NASDAQ:ATXI – Get Free Report) will likely be releasing its resultson Monday, August 10th. Analysts expect the company to post earnings of ($56.25) per share for the quarter.

Avenue Therapeutics Price Performance

Avenue Therapeutics stock opened at $0.39 on Monday. The firm has a market cap of $1.28 million, a price-to-earnings ratio of 0.02 and a beta of -0.17. Avenue Therapeutics has a fifty-two week low of $0.15 and a fifty-two week high of $0.97. The firm has a fifty day moving average price of $0.31 and a two-hundred day moving average price of $0.33.

About Avenue Therapeutics

(Get Free Report)

Avenue Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for disorders of the central nervous system, with an initial emphasis on acute pain management. The company’s research and development efforts are centered on reformulating established active pharmaceutical ingredients to address unmet needs in hospital and outpatient settings, aiming to improve safety profiles, reduce opioid exposure and support enhanced patient recovery.

The company’s lead product candidate is intravenous tramadol, a unique non-solicited opioid analgesic that combines dual mechanisms of action to manage moderate to severe acute pain.

Read More